Financial Tear Sheet

Corporate Profile

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of over $10 billion in 2017. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com.

More Information

Primary IR Contact
Scott Frommer
Vice President, Investor Relations
Laboratory Corporation of America Holdings
Phone: 336-436-5076
Fax: 336-436-1569
E-mail: investor@labcorp.com

Stock Performance
LH (Common)
ExchangeNYSE (US Dollar)
Price$150.17
Change (%) Stock is Up 3.41 (2.32%)
Volume1,663,437
52 Week Low$119.38
Market Cap$15,152,153,000
Rolling EPS8.61
PE Ratio17.4413
Shares Outstanding100,900,000
Data as of 02/15/19 4:02 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: LH.  Currently trading at $150.17 with a 52 week high of $190.35 and a 52 week low of $119.38.
Recent News & Events
02/07/19 - 6:55 a.m.
LabCorp Announces 2018 Fourth Quarter and Full Year Results and Provides 2019 Guidance
01/22/19 - 10:35 a.m.
LabCorp Named to FORTUNE Magazine's 2019 List of ‘World’s Most Admired Companies,’ Making the Annual List for the Second Consecutive Year
01/16/19 - 8:45 a.m.
LabCorp to Announce Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019
There are currently no events scheduled.
Analyst Estimates / Ratings
Mean Recommendation: 2.4

Buy
SellStrong Buy
Unable to fulfill request.
SEC Filings
Filing DateForm
02/14/194 XBRL SEC Filing Unavailable
02/14/194 XBRL SEC Filing Unavailable
02/14/194 XBRL SEC Filing Unavailable
02/14/194 XBRL SEC Filing Unavailable
Corporate Governance
David P.  KingChairman and Chief Executive Officer
Glenn A. EisenbergExecutive Vice President and Chief Financial Officer
John D.  RatliffChief Executive Officer, Covance Drug Development
Lance V. BerberianSenior Vice President and Chief Information Officer
Edward T. DodsonSenior Vice President and Chief Accounting Officer
F. Samuel Eberts IIISenior Vice President, Chief Legal Officer and Secretary
Lisa J. UthgenanntChief Human Resources Officer
Brian J. CaveneyChief Medical Officer
Ownership Summary
Shareholders
 HoldersValue ($MM)% O/SShares
Institution1,04012,143.4793.594,290,111
Mutual Fund1,5996,781.5648.048,462,511
Insider *1861.820.4443,195
*Insider values reflect direct beneficial ownership.
Top Holders
 Shares Held% O/SShare ChangeFiling Date
The Vanguard Group, Inc.10,880,74310.857,07612/31/18
BlackRock Institutional Trust Company, N.A.5,940,2475.9296,01812/31/18
State Street Global Advisors (US)4,254,3034.24,52712/31/18
Boston Partners3,269,2683.2-1,195,80612/31/18
Nordea Funds Oy2,120,5092.1143,42612/31/18
Amundi Pioneer Asset Management, Inc.1,524,3951.5-400,85912/31/18
JP Morgan Asset Management1,484,8671.516,87112/31/18
Dimensional Fund Advisors, L.P.1,460,2141.534,79712/31/18
Geode Capital Management, L.L.C.1,412,0931.4111,85912/31/18
BlackRock Investment Management, LLC1,250,9381.2133,66412/31/18